ValuEngine downgraded shares of Forward Pharma A/S (NASDAQ:FWP) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

Separately, BidaskClub raised shares of Forward Pharma A/S from a hold rating to a buy rating in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $24.00.

Shares of Forward Pharma A/S (NASDAQ:FWP) traded up 1.64% during mid-day trading on Tuesday, reaching $6.21. 141,042 shares of the company’s stock traded hands. The company’s 50 day moving average is $23.01 and its 200-day moving average is $22.15. The firm’s market cap is $293.01 million. Forward Pharma A/S has a 52 week low of $5.46 and a 52 week high of $33.00.

COPYRIGHT VIOLATION WARNING: “ValuEngine Downgrades Forward Pharma A/S (FWP) to Sell” was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/16/valuengine-downgrades-forward-pharma-as-fwp-to-sell.html.

The business also recently disclosed an annual dividend, which was paid on Monday, September 11th. Investors of record on Thursday, September 7th were given a $22.903 dividend. The ex-dividend date was Wednesday, September 6th. Forward Pharma A/S’s dividend payout ratio is currently -3,249.25%.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Baupost Group LLC MA lifted its position in Forward Pharma A/S by 3.9% in the 1st quarter. Baupost Group LLC MA now owns 5,575,407 shares of the biotechnology company’s stock valued at $119,927,000 after acquiring an additional 208,107 shares in the last quarter. BlueMountain Capital Management LLC lifted its position in Forward Pharma A/S by 15.3% in the 2nd quarter. BlueMountain Capital Management LLC now owns 1,511,043 shares of the biotechnology company’s stock valued at $26,982,000 after acquiring an additional 200,000 shares in the last quarter. Senzar Asset Management LLC lifted its position in Forward Pharma A/S by 38.2% in the 2nd quarter. Senzar Asset Management LLC now owns 652,500 shares of the biotechnology company’s stock valued at $13,265,000 after acquiring an additional 180,200 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Forward Pharma A/S in the 1st quarter valued at $2,465,000. Finally, Alps Advisors Inc. bought a new stake in Forward Pharma A/S in the 2nd quarter valued at $866,000. 21.85% of the stock is currently owned by institutional investors and hedge funds.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.